INTRODUCTION
Inflammatory bowel disease (IBD) comprising Crohn's disease (CD) and ulcerative colitis (UC) affect an estimated 1.5 million Americans, 2.2 million individuals in Europe, and several thousands more worldwide. 1, 2 The therapeutic goal has evolved from relief of IBD-related symptoms to the more ambitious goal of mucosal healing, though considerable debate exists about the optimal definition for this endpoint. [3] [4] [5] [6] [7] [8] Supporting this is the recognition that symptom-based disease activity scores, long widely used as markers of efficacy, correlate poorly with endoscopic inflammation. 9, 10 In addition, emerging longitudinal data suggests that individuals who are able to attain mucosal healing have a superior long-term prognosis including a lower risk of surgery, hospitalisations, and need for systemic steroids. 4, 6, [11] [12] [13] [14] The past two decades have witnessed a significant expansion in the number of treatment options available for CD and UC, initially with monoclonal antibodies against tumour necrosis factor a (anti-TNF) (infliximab, adalimumab, certolizumab pegol, golimumab), and subsequently anti-integrin (natalizumab, vedolizumab) therapies. In addition, there is recognition that use of these biologics in combination with a conventional immunosuppressive (azathioprine, mercaptopurine, methotrexate) may yield superior outcomes and improve durability of therapy. 15, 16 Thus, with this increase in the number of individual drugs with distinct mechanisms of action as well as possibility of combination therapy, it is increasingly important that appropriate positioning of therapies within the treatment algorithm must be informed by comparative effectiveness and safety. While a few recent studies have provided such comparisons, [17] [18] [19] [20] [21] many examined only clinical outcomes of remission and response. The few examining mucosal healing as an endpoint were restricted to UC and focused on biological therapies, and did not examine the utility of combination with a conventional immunosuppressive. 17, [22] [23] [24] With this evolution of therapeutic goals, there is an important need for comparing the effectiveness of these agents in achieving the preferred endpoint of mucosal healing. Recent reviews have thus far been restricted to a single therapeutic class and failed to provide pairwise comparisons. 25 To address this gap in the literature, we performed this systematic review and network metaanalysis of relevant randomised controlled trials to (i) examine the efficacy of each therapeutic class in inducing and maintaining mucosal healing in moderate-to-severe CD and UC; and (ii) to perform network meta-analysis utilising direct and indirect evidence from clinical trials to derive comparative efficacy of various therapies in achieving mucosal healing.
METHODS
Data sources and study selection A full overview of the search strategy is presented in Data S1. In brief, a systematic electronic search was performed on MEDLINE/PUBMED and EMBASE to identify relevant full-text articles published between 1980 and 2015 examining mucosal healing as an outcome in randomised controlled trials in moderate-to-severe CD or UC.
Inclusion and exclusion criteria
To be eligible for inclusion, we required the study to be (i) a randomised controlled trial in adult patients with moderate-to-severe CD or UC including either a placebo arm or two active treatment arms; (ii) examined medications currently approved by the United States Food and Drug Administration (FDA) for treatment of CD or UC (azathioprine, methotrexate, mercaptopurine, infliximab, adalimumab, certolizumab, golimumab, natalizumab, vedolizumab); (iii) examine mucosal healing as an endpoint and (iv) were available in full text in the English language. Our exclusion criteria included studies of medications used only in mild-to-moderate CD or UC (budesonide, 5-aminosalicylates), and those that were observational, nonrandomised or open label.
Data collection
The decision for inclusion of the study was made independently by two authors (AC, ANA) and disagreements settled through consensus. Data were extracted on the number of cases receiving active treatment(s) or placebo, the type, dose and interval of active treatment(s), and duration of follow-up. For each included trial, the scoring system used to assess endoscopic endpoints was extracted, and mucosal healing defined as per the criteria used for each trial. For trials where there was more than one dose arm of an active treatment, the pooled estimates were included if both doses were used commonly in clinical practice (e.g. infliximab 5 mg/kg and 10 mg/ kg). On the other hand, if the dosing in one arm was not commonly used in clinical practice (adalimumab 80/ 40 mg or golimumab 400/200 mg), then only data from the United States Food and Drug Administration approved dosing arm was used.
Study quality was assessed using the Cochrane collaboration tool assessing risk of bias in several domains -blinding of investigators, blinding of participants, personnel, and outcome assessors, completeness of outcome data, reporting of selected outcomes, random sequence generation, allocation concealment and other sources of bias. 26 Studies judged to be at low risk in all domains were considered to be at a low risk of bias.
Statistical analysis -direct comparisons
Pooled absolute rates and odds ratios (OR) of mucosal healing for all treatments compared to placebo using direct comparisons was calculated using a random-effect model using the DerSimonian-Laird weights. 27 A sensitivity analysis was performed using fixed-effect models, and results are reported separately if they differed from the random-effect model. Heterogeneity was assessed using the Cochrane's Q and i 2 statistic with values > 50% and P < 0.10 indicating significant heterogeneity. Analyses were performed separately for CD and UC, and induction and maintenance trials respectively. Trials that assessed mucosal healing at <24 weeks were considered induction trials while those that assessed it beyond this were considered maintenance studies. If a study offered endpoints at two different time points within the same time category (e.g. at week 30 and week 52), the later time point was used in the analysis. We assessed for publication bias using the Begg's and Egger's tests and constructed funnel plots to determine asymmetry. A P < 0.05 indicated statistical significance for all tests. Direct comparisons were performed using STATA 13.2 (StataCorp, College Station, TX, USA).
Pairwise comparisons -network meta-analysis We conducted a random-effect Bayesian network meta-analysis to inform pairwise comparative efficacy of different treatments in the induction and maintenance of mucosal healing. 28, 29 Similar to a traditional meta-analysis, this model assumes that each trial for a pair of treatments estimates a mean treatment, which varied around a common mean with a shared between-study variance. However, with a network meta-analysis, each mean treatment effect is broken down into basic "parameters" that are unique for each intervention. By setting the treatment effect for an arbitrary reference treatment to zero (we chose placebo), we then compared these basic parameters to calculate the treatment effect (log odds ratio) and 95% credible interval (CrI) and the probability of superiority/inferiority between every pair of treatments. A probability of superiority of ≥97.5% corresponds to a credible interval that does not overlap 1 and was considered statistically significant. For comparisons where direct and indirect comparisons were combined, potential inconsistency was assessed.
As mucosal healing is a rare outcome and the networks included a relatively small number of studies, it is difficult to obtain a reliable estimate of the between-study heterogeneity in a random-effect network meta-analysis. We relied on an advantage of Bayesian analyses, which require the specification of a prior distribution for each model parameter. For our primary analysis, we used the published prior of Turner for the between-study variability in a semi-objective outcome in trials of drug vs. placebo. 30 We conducted sensitivity analyses using an uninformative prior in a random-effect model and a fixed-effect model (which assumes there is no between-study variability). All chains were run with 10 000 burn-in iterations followed by 10 000 monitoring iterations. Convergence was assessed by running three chains, inspecting the sampling history plots, and calculating Gelman-Rubin-Brooke statistics. All Bayesian analyses were conducted using R statistical software 2.15.2 with the rjags package version 3.3.0 (www.r-projec t.org).
RESULTS

Literature search
Our literature search identified 1608 relevant articles on Pubmed and 1585 relevant articles on Embase. Following title and abstract and full-text review, 12 eligible randomised controlled trials were included in our study (Figure 1) . Nine trials compared active treatment to placebo, [31] [32] [33] [34] [35] [36] [37] [38] [39] three trials compared combination therapy to azathioprine alone 15, 16, 40 and two against infliximab. 15, 16 The duration of follow-up at assessment of mucosal healing ranged from 6 to 12 weeks for the induction trials, and 32-54 weeks for the maintenance trials. The proportion of patients receiving concomitant therapy with corticosteroids at study entry ranged from 14% to 63% among active treatment, and 39% to 65% among placebo. Among studies allowing concomitant therapy with immunosuppressives; the proportion receiving IMM therapy ranged from 14% to 55%. All CD trials utilised the Crohn's disease endoscopic index of severity (CDEIS) as the endoscopic endpoint, defining mucosal healing as the absence of ulcerations. 16, 32, 34, 40 All UC trials used the Mayo endoscopic score mucosal healing, defining healing as a score of 0 or 1.
Direct treatment comparisons
Crohn's disease. Induction of remission: Two trials, one each with infliximab 32 and adalimumab, 34 examined induction of mucosal healing in CD, contributing 94 patients receiving anti-TNF and 77 placebo 32, 34 ( Table 1 ). The pooled rates of mucosal healing with treatment and placebo were 29% and 7%. In a randomeffect model, anti-TNF biologics were more effective for the induction of mucosal healing than placebo with an OR of 3. Infliximab and adalimumab individually demonstrated a nonstatistically significant trend towards superiority over placebo.
Maintenance of remission: This endpoint was examined by two placebo-controlled trials, one each of infliximab 32 and adalimumab, 34 and two comparing combination infliximab/azathioprine therapy to either azathioprine 16, 40 or infliximab alone. 16 In the two placebocontrolled trials including a total of 88 patients on anti-TNF and 75 on placebo, 32, 34 the pooled rates of mucosal healing were 28% and 1% with active treatment or placebo, respectively, with an OR of 19.71 (95% CI 3.51-110.84) (Figure 2b ). In the SONIC trial comparing azathioprine, infliximab and combination therapy reported rates of mucosal healing of 17%, 30% and 44%, respectively, with combination therapy having statistically significant higher rates of mucosal healing than thiopurine monotherapy, 16 studies (Figure 3a ). Both anti-TNF biologics (OR 1.98, 95% CI 1.46-2.69) and anti-integrins (OR 2.09, 95% CI 1.33-3.31) achieved statistically significant effects as a therapeutic class. In the active comparator UC SUCCESS trial, mucosal healing occurred at similar rates in the combination therapy (63%) and infliximab (55%) arms, both statistically superior to azathioprine alone (37%). 15 Maintenance of remission. This analysis utilised data from 822 patients receiving active treatment and 745 receiving placebo, with two trials on adalimumab, 38, 41 and one each of infliximab, 33 golimumab 36 or vedolizumab. 31 The pooled rates of mucosal healing with biologics and placebo were 33% and 18% respectively (OR 2.59, 95% CI 1.84-3.66) (Figure 3b ). The pooled estimates separately for anti-TNF biologics (OR 2.27, 95% CI 1.67-3.07) and anti-integrin (OR 4.31, 95% CI 2.45-7.58) were also both statistically significant.
Network meta-analysis
Crohn's disease. A network meta-analysis was not possible for induction trials in CD, as the model did not converge due to sparse data. Table 3 presents the results of the network meta-analysis for maintenance of mucosal healing ( Figure S1 ). Both infliximab (OR 17.98, 95% CrI 2.02-390.97, 99% probability of superiority) and combination therapy (OR 30.12, 95 CrI 2.45-734.77, 99% probability of superiority) were more effective than placebo in maintaining mucosal healing but the estimates were imprecise and the confidence intervals wide. Combination therapy demonstrated a nonsignificant trend towards superiority over azathioprine monotherapy, with a 97% probability of superiority. The treatment effect for adalimumab was not estimable, due to sparse data and lack of convergence.
Ulcerative colitis. Table 4 presents the results of the network meta-analysis for induction of mucosal healing in UC ( Figure S2a) . Consistent with the direct comparisons, all treatments except azathioprine were superior to placebo for induction of mucosal healing. Pairwise comparisons revealed adalimumab therapy to be inferior to infliximab (OR 0.45, 95% CrI 0.25-0.82) and combination infliximab-azathioprine (OR 0.32, 95% CrI 0.12-0.84) for inducing mucosal healing. Combination infliximab-azathioprine was also statistically superior to azathioprine monotherapy (OR 2.86, 95% CrI 1.35-6.54), with a trend towards superiority over golimumab (96% probability of superiority) and vedolizumab (93% probability of superiority). Infliximab had nonsignificant 95% probability of superiority over golimumab and 88% superiority to vedolizumab. The results of the network meta-analysis of therapies in maintaining mucosal healing in UC are presented in Table 5 ( Figure S2b ). All treatments were statistically superior to placebo except golimumab which achieved a All studies used the Crohn's disease endoscopic index of severity (CDEIS) for endoscopic assessment and defined mucosal healing as the absence of ulcerations.
96% probability of superiority. While none of the pairwise active treatment comparisons reached statistical significance, vedolizumab demonstrated a 95% and 93% probability of superiority over adalimumab and golimumab for maintenance of remission respectively.
Publication bias and study quality None of the included studies were deemed high risk in any of the assessment categories and all were considered to be a low risk of bias (Table S1 ). There were too few studies to robustly test for significant publication bias.
DISCUSSION
Mucosal healing has emerged as an important therapeutic endpoint in the management of inflammatory bowel diseases. 3, 4, 8, 25, 42 However, few clinical trials thus far have incorporated it as an outcome and limited data exist to guide selection of therapy based on their comparative effectiveness in achieving this endpoint. In this systematic review and network meta-analysis, we confirm that anti-TNF biologics are effective in inducing and maintaining mucosal healing in CD and UC while antiintegrin therapies are effective in inducing and maintaining mucosal healing in UC. Randomised controlled trials, summarised in meta-analyses, have confirmed the effectiveness of both anti-TNF and anti-integrin therapies in inducing and maintaining clinical remission in CD and UC. 17, 18, [43] [44] [45] [46] [47] These trials have resulted in the approval of three anti-TNF therapies each for CD and UC, two anti-integrin therapies for CD and one for UC. However, high quality mucosal healing data are scarce, particularly for CD where we were able to identify RCT data examining induction of mucosal healing for only two of the approved therapies -infliximab and adalimumab.
32, 34
Overall (I-squared = 36.2%, P = 0.211) The MUSIC trial with certolizumab pegol was open label and without a placebo arm, 48 while the GEMINI trial for vedolizumab in CD did not provide data on mucosal healing. 39 Most prior systematic reviews have focused on clinical endpoints of response and remission without an examination of mucosal healing. 17, 18, [43] [44] [45] [46] [47] Arguably for both diseases, the latter is a more relevant endpoint for several reasons. First, symptom-based disease activity scores have a notoriously poor correlation with objective severity of inflammation. 9, 10, [49] [50] [51] In cross-sectional studies, endoscopic severity, serologic inflammatory markers, and faecal calprotectin correlate more strongly with each other than with the CDAI. 9, 10 While symptoms are important determinants of health-related quality of life in IBD, endoscopic severity of inflammation may be a stronger indicator of ongoing bowel damage and need for surgery. In a prospective Norwegian cohort, mucosal healing was associated with reduced risk of colectomy in UC and lower inflammation at 5 years and reduced need for corticosteroid treatment in CD, 4 findings confirmed by a recent meta-analysis. 6 In a cohort of 214 CD patients initiating therapy with infliximab, Schnitzler et al., demonstrated that mucosal healing was associated with a decreased need for surgery during long-term follow-up; patients who achieved mucosal healing had less than half the rate of surgery as those not achieving healing. 11 Consistent with these findings, an international consensus panel recently recommended mucosal healing as an important therapeutic goal for both CD and UC. 8 A second significant finding from our systematic review is the pairwise comparisons from the network meta-analysis, particularly in UC. Importantly, both infliximab alone and in combination with azathioprine were superior to adalimumab for induction of mucosal healing in UC with a trend towards superiority over golimumab. Combination therapy also demonstrated a trend towards superiority over vedolizumab suggesting that in CD patients also similarly suggested that infliximab may be the preferred agent for induction of clinical remission in CD. 19 Hazelwood et al. performed a more extensive analysis including studies with immunosuppressant monotherapy and combination anti-TNF immunosuppressive therapy and identified superiority of a combination of infliximab and azathioprine or adalimumab monotherapy over other immunosuppressive and anti-TNF agents for induction and maintenance of remission in CD. 18 As an explanation for discrepant results of superiority of ADA over IFX in CD, but inferiority in 
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UC, it is possible that the greater mucosal burden of inflammation in UC resulting in mucosal drug loss, 52 may perhaps mandate a higher dosing of ADA for induction of clinical and endoscopic remission in UC than CD. While trials examining this hypothesis are ongoing, this finding also highlights that strategies preferred in one disease may not be applicable to the other. Thus, the bulk of data points towards the short-term superiority of infliximab over adalimumab in UC. This may be due to intravenous administration of infliximab, higher tissue concentrations particularly in severe colitis given the weight based dose, and quicker onset of action. However, such findings should also be interpreted cautiously for a few reasons. First, the number of included trials was small and there were no direct head-to-head comparisons. Second, the populations eligible for inclusion in the trials were different -initial trials of infliximab comprised of anti-TNF na€ ıve patients while significant proportions of patients included in latter anti-TNF trials had prior anti-TNF exposure. This heterogeneity between the trials highlights the important additional need for direct head-to-head comparison studies to accurately inform our choices.
In contrast, there were no statistically significant differences in pairwise comparisons for maintenance of mucosal healing, though vedolizumab showed at trend towards superiority over adalimumab and golimumab. At present, selection of therapies is often influenced by familiarity with drugs and health plan coverage, often resulting in an initial trial of one or more anti-TNFs followed by the newer anti-integrin therapy. However, the finding of a trend towards superiority of vedolizumab over golimumab and adalimumab provocatively raises the question of whether the anti-integrin should be preferred over injectable anti-TNF biologics if the superior efficacy can be robustly confirmed.
In addition to the need for additional data, there are several questions about mucosal healing that remain unanswered. All the trials included in our network metaanalysis had similar definitions of mucosal healing. However, there remains a robust debate in the literature about what constitutes complete mucosal healing in clinical practice, and if histological endpoints need to be examined as well. Although in clinical trials in UC, both a Mayo endoscopic score of 0 or 1 are considered endoscopic remission, data suggest that a Mayo endoscopic sub-score of 1 is associated with an increased risk of relapse compared to a sub-score of 0. 53 In observational studies, histological grade of inflammation was predictive of clinical relapse even after factoring in for endoscopic healing. 54 As more rigorous definitions of mucosal healing are validated and their clinical utility confirmed, further comparative effectiveness analyses may be warranted. As well, therapeutic drug monitoring and either reactive or proactive therapy escalation are not included in the protocol within the clinical trials that informed our network meta-analysis. Dose escalation can modify efficacy and pairwise comparative effectiveness. This topic attains particular urgency and importance given increasing regulatory requirements for inclusion as endpoint in clinical trials prior to drug approval. We readily acknowledge several limitations to our study. First, particularly for CD, the number of included trials was few. Thus, pooled effect sizes and indirect treatment comparisons yielded wide confidence intervals. In addition, placebo-controlled RCT mucosal healing data was not available for immunosuppressives, certolizumab pegol, natalizumab and vedolizumab in CD. Consequently, between-class comparisons for anti-TNF and anti-integrin therapies could not be performed in CD. Thus, there is an important need for mucosal healing data for all available therapies as well as larger studies of mucosal healing with infliximab and adalimumab to perform robust meaningful comparisons. Second, individual patient-level data were not available to examine impact of combination therapy or other clinical covariates on mucosal healing. We found weak evidence of publication bias for trials examining maintenance of mucosal healing in UC, emphasising the need for more studies examining this outcome to robustly inform comparative efficacy estimates.
In conclusion, we demonstrate that both anti-TNF and anti-integrin biological agents are effective for inducing and maintaining mucosal healing in UC, and anti-TNF therapies in CD. However, between-drug differences in efficacy exist within each therapeutic class, particularly for induction of mucosal healing in UC, mucosal healing infliximab or combination therapy being the preferred strategy. There is an important and urgent need for data demonstrating efficacy of all approved agents in achieving mucosal healing to truly inform comparative effectiveness. While indirect treatment comparisons are informative, they do not supplant the need for direct head-to-head studies to truly inform patient care and guide therapeutic choices to achieve better outcomes.
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